| Clinical implications of PTEN loss in prostate cancer |
73 |
| Genetics of male infertility |
66 |
| Cellular plasticity and the neuroendocrine phenotype in prostate cancer |
55 |
| The inflammatory microenvironment and microbiome in prostate cancer development |
44 |
| Mechanisms of BCG immunotherapy and its outlook for bladder cancer |
43 |
| Sexual dysfunction and male infertility |
38 |
| The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications |
36 |
| A new era: artificial intelligence and machine learning in prostate cancer |
32 |
| Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy |
25 |
| Long non-coding RNAs in genitourinary malignancies: a whole new world |
24 |
| Advances in laser technology and fibre-optic delivery systems in lithotripsy |
23 |
| Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management |
20 |
| Towards precision oncology in advanced prostate cancer |
19 |
| Persistence and clinical relevance of Zika virus in the male genital tract |
18 |
| Nonantibiotic prevention and management of recurrent urinary tract infection |
18 |
| Cancer metabolomic markers in urine: evidence, techniques and recommendations |
18 |
| Molecular and histopathology directed therapy for advanced bladder cancer |
17 |
| Epigenetics in renal cell cancer: mechanisms and clinical applications |
16 |
| Community profiling of the urinary microbiota: considerations for low-biomass samples |
15 |
| The influence of BRCA2 mutation on localized prostate cancer |
15 |
| The UMBRELLA SIOP-RTSG 2016 Wilms tumour pathology and molecular biology protocol |
14 |
| Pelvic lymph node dissection during radical cystectomy for muscle-invasive bladder cancer |
14 |
| Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition |
14 |
| Translational models of prostate cancer bone metastasis |
13 |
| The multifaceted immune regulation of bladder cancer |
13 |
| Epigenetic modifiers: activities in renal cell carcinoma |
13 |
| Nonsurgical management of Peyronie's disease |
13 |
| Urologic chronic pelvic pain syndrome: insights from the MAPP Research Network |
12 |
| Harnessing the mesenchymal stem cell secretome for regenerative urology |
12 |
| Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis |
11 |
| Intracytoplasmic sperm injection for male infertility and consequences for offspring |
11 |
| Intravesical device-assisted therapies for non-muscle-invasive bladder cancer |
11 |
| Bladder biomechanics and the use of scaffolds for regenerative medicine in the urinary bladder |
11 |
| T1 bladder cancer: current considerations for diagnosis and management |
11 |
| Technologies for image-guided surgery for managing lymphatic metastases in prostate cancer |
10 |
| Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018 |
10 |
| Landmarks in vaginal mesh development: polypropylene mesh for treatment of SUI and POP |
9 |
| Unravelling disparate roles of NOTCH in bladder cancer |
9 |
| Regulation of masculinization: androgen signalling for external genitalia development |
9 |
| Optimizing pharmacokinetics of intravesical chemotherapy for bladder cancer |
9 |
| Landmarks in prostate cancer |
9 |
| The potential of 3D printing in urological research and patient care |
9 |
| The seminal microbiome in health and disease |
9 |
| HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer |
8 |
| Potentiating prostate cancer immunotherapy with oncolytic viruses |
8 |
| Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies |
8 |
| Historical and contemporary perspectives on cribriform morphology in prostate cancer |
8 |
| Personalization of prostate cancer therapy through phosphoproteomics |
8 |
| Radium-223 mechanism of action: implications for use in treatment combinations |
8 |
| Supporting sexuality and improving sexual function in transgender persons |
7 |
